Mediwound Ltd (NASDAQ:MDWD)‘s stock had its “buy” rating reissued by Brean Capital in a research report issued on Tuesday, Analyst Ratings.Net reports. They currently have a $20.00 price target on the biopharmaceutical company’s stock. Brean Capital’s price target would suggest a potential upside of 211.53% from the stock’s previous close.

Shares of Mediwound (NASDAQ:MDWD) traded up 5.25% during trading on Tuesday, hitting $6.42. 52,546 shares of the stock were exchanged. Mediwound has a one year low of $5.00 and a one year high of $10.47. The company’s market cap is $139.96 million. The stock’s 50 day moving average price is $8.48 and its 200-day moving average price is $8.05.

Mediwound (NASDAQ:MDWD) last released its earnings results on Monday, January 25th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.13. The firm had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.40 million. The firm’s quarterly revenue was up 125.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.33) earnings per share. On average, analysts predict that Mediwound will post ($0.95) EPS for the current year.

MDWD has been the topic of a number of other reports. Zacks Investment Research restated a “buy” rating and set a $9.00 price target on shares of Mediwound in a research report on Saturday, January 16th. Oppenheimer restated an “outperform” rating and set a $13.00 price target on shares of Mediwound in a research report on Tuesday. Five analysts have rated the stock with a buy rating, Mediwound has a consensus rating of “Buy” and a consensus price target of $13.65.

MediWound Ltd. is a fully integrated biopharmaceutical company. The Company is focused on developing, manufacturing and commercializing products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds and connective tissue disorders. The Company’s biopharmaceutical product, NexoBrid, which is based on its patented proteolytic enzyme technology, represents a new paradigm in burn care management, and its clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier upon patient admission, without harming viable tissues. The Company launched NexoBrid in December 2013 in the European Union through its wholly-owned German subsidiary, targeting a focused audience of burn specialists treating patients in burn centers and hospital burn units.

12 Month Chart for NASDAQ:MDWD

Receive News & Ratings for Mediwound Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound Ltd and related companies with MarketBeat.com's FREE daily email newsletter.